|
1
|
Hershko A, Ciechanover A and Varshavsky A:
The ubiquitin system. Nat Med. 6:1073–1081. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Crusio KM, King B, Reavie LB and Aifantis
I: The ubiquitous nature of cancer: The role of the SCF(Fbw7)
complex in development and transformation. Oncogene. 29:4865–4873.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shimizu K, Nihira NT, Inuzuka H and Wei W:
Physiological functions of FBW7 in cancer and metabolism. Cell
Signal. 46:15–22. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Uddin S, Bhat AA, Krishnankutty R, Mir F,
Kulinski M and Mohammad RM: Involvement of F-BOX proteins in
progression and development of human malignancies. Semin Cancer
Biol. 36:18–32. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Thompson BJ, Buonamici S, Sulis ML,
Palomero T, Vilimas T, Basso G, Ferrando A and Aifantis I: The
SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell
leukemia. J Exp Med. 204:1825–1835. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Welcker M and Clurman BE: FBW7 ubiquitin
ligase: A tumour suppressor at the crossroads of cell division,
growth and differentiation. Nat Rev Cancer. 8:83–93. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tan Y, Sangfelt O and Spruck C: The
Fbxw7/hCdc4 tumor suppressor in human cancer. Cancer Lett.
271:1–12. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Spruck CH, Strohmaier H, Sangfelt O,
Müller HM, Hubalek M, Müller-Holzner E, Marth C, Widschwendter M
and Reed SI: hCDC4 gene mutations in endometrial cancer. Cancer
Res. 62:4535–4539. 2002.PubMed/NCBI
|
|
9
|
Davis RJ, Welcker M and Clurman BE: Tumor
suppression by the Fbw7 ubiquitin ligase: Mechanisms and
opportunities. Cancer Cell. 26:455–464. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hao B, Oehlmann S, Sowa ME, Harper JW and
Pavletich NP: Structure of a Fbw7-Skp1-cyclin E complex:
Multisite-phosphorylated substrate recognition by SCF ubiquitin
ligases. Mol Cell. 26:131–143. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Welcker M, Larimore EA, Swanger J,
Bengoechea-Alonso MT, Grim JE, Ericsson J, Zheng N and Clurman BE:
Fbw7 dimerization determines the specificity and robustness of
substrate degradation. Genes Dev. 27:2531–2536. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Crusio K M, King B, Reavie L B and
Aifantis I: The ubiquitous nature of cancer: the role of the SCF
Fbw7 complex in development and transformation. Oncogene.
29:4865–4873. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tang X, Orlicky S, Lin Z, Willems A,
Neculai D, Ceccarelli D, Mercurio F, Shilton BH, Sicheri F and
Tyers M: Suprafacial orientation of the SCFCdc4 dimer accommodates
multiple geometries for substrate ubiquitination. Cell.
129:1165–1176. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Welcker M, Orian A, Jin J, Grim JE, Harper
JW, Eisenman RN and Clurman BE: The Fbw7 tumor suppressor regulates
glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein
degradation. Proc Natl Acad Sci USA. 101:9085–9090. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Busino L, Millman SE, Scotto L, Kyratsous
CA, Basrur V, O'Connor O, Hoffmann A, Elenitoba-Johnson KS and
Pagano M: Fbxw7α- and GSK3-mediated degradation of p100 is a
pro-survival mechanism in multiple myeloma. Nat Cell Biol.
14:375–385. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yada M, Hatakeyama S, Kamura T, Nishiyama
M, Tsunematsu R, Imaki H, Ishida N, Okumura F, Nakayama K and
Nakayama KI: Phosphorylation-dependent degradation of c-Myc is
mediated by the F-box protein Fbw7. EMBO J. 23:2116–2125. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Welcker M, Orian A, Grim JE, Eisenman RN
and Clurman BE: A nucleolar isoform of the Fbw7 ubiquitin ligase
regulates c-Myc and cell size. Curr Biol. 14:1852–1857. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Koepp DM, Schaefer LK, Ye X, Keyomarsi K,
Chu C, Harper JW and Elledge SJ: Phosphorylation-dependent
ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase.
Science. 294:173–177. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Weng AP, Ferrando AA, Lee W, Morris JP IV,
Silverman LB, Sanchez-Irizarry C, Blacklow SC, Look AT and Aster
JC: Activating mutations of NOTCH1 in human T cell acute
lymphoblastic leukemia. Science. 306:269–271. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fukushima H, Matsumoto A, Inuzuka H, Zhai
B, Lau AW, Wan L, Gao D, Shaik S, Yuan M, Gygi SP, et al: SCF(Fbw7)
modulates the NFkB signaling pathway by targeting NFkB2 for
ubiquitination and destruction. Cell Rep. 1:434–443. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wei W, Jin J, Schlisio S, Harper JW and
Kaelin WG Jr: The v-Jun point mutation allows c-Jun to escape
GSK3-dependent recognition and destruction by the Fbw7 ubiquitin
ligase. Cancer Cell. 8:25–33. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lochab S, Pal P, Kapoor I, Kanaujiya JK,
Sanyal S, Behre G and Trivedi AK: E3 ubiquitin ligase Fbw7
negatively regulates granulocytic differentiation by targeting
G-CSFR for degradation. Biochim Biophys Acta. 1833:2639–2652. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xie CM and Sun Y: The MTORC1-mediated
autophagy is regulated by the FBXW7-SHOC2-RPTOR axis. Autophagy.
15:1470–1472. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huang L-Y, Zhao J, Chen H, Wan L, Inuzuka
H, Guo J, Fu X, Zhai Y, Lu Z, Wang X, et al: SCFFBW7-mediated
degradation of Brg1 suppresses gastric cancer metastasis. Nat
Commun. 9:35692018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Finkin S, Aylon Y, Anzi S, Oren M and
Shaulian E: Fbw7 regulates the activity of endoreduplication
mediators and the p53 pathway to prevent drug-induced polyploidy.
Oncogene. 27:4411–4421. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu N, Li H, Li S, Shen M, Xiao N, Chen Y,
Wang Y, Wang W, Wang R, Wang Q, et al: The Fbw7/human CDC4 tumor
suppressor targets proproliferative factor KLF5 for ubiquitination
and degradation through multiple phosphodegron motifs. J Biol Chem.
285:18858–18867. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kourtis N, Moubarak RS, Aranda-Orgilles B,
Lui K, Aydin IT, Trimarchi T, Darvishian F, Salvaggio C, Zhong J,
Bhatt K, et al: FBXW7 modulates cellular stress response and
metastatic potential through HSF1 post-translational modification.
Nat Cell Biol. 17:322–332. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bengoechea-Alonso MT and Ericsson J: The
ubiquitin ligase Fbxw7 controls adipocyte differentiation by
targeting C/EBPalpha for degradation. Proc Natl Acad Sci USA.
107:11817–11822. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Akhoondi S, Lindström L, Widschwendter M,
Corcoran M, Bergh J, Spruck C, Grandér D and Sangfelt O:
Inactivation of FBW7/hCDC4-beta expression by promoter
hypermethylation is associated with favorable prognosis in primary
breast cancer. Breast Cancer Res. 12:R1052010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mao JH, Kim IJ, Wu D, Climent J, Kang HC,
DelRosario R and Balmain A: FBXW7 targets mTOR for degradation and
cooperates with PTEN in tumor suppression. Science. 321:1499–1502.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Akhoondi S, Sun D, von der Lehr N,
Apostolidou S, Klotz K, Maljukova A, Cepeda D, Fiegl H, Dafou D,
Marth C, et al: FBXW7/hCDC4 is a general tumor suppressor in human
cancer. Cancer Res. 67:9006–9012. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Perry JM and Li L: Self-renewal versus
transformation: Fbxw7 deletion leads to stem cell activation and
leukemogenesis. Genes Dev. 22:1107–1109. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kimura T, Gotoh M, Nakamura Y and Arakawa
H: hCDC4b, a regulator of cyclin E, as a direct transcriptional
target of p53. Cancer Sci. 94:431–436. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mansour MR, Sanda T, Lawton LN, Li X,
Kreslavsky T, Novina CD, Brand M, Gutierrez A, Kelliher MA,
Jamieson CH, et al: The TAL1 complex targets the FBXW7 tumor
suppressor by activating miR-223 in human T cell acute
lymphoblastic leukemia. J Exp Med. 210:1545–1557. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xiang J, Hang JB, Che JM and Li HC: MiR-25
is up-regulated in non-small cell lung cancer and promotes cell
proliferation and motility by targeting FBXW7. Int J Clin Exp
Pathol. 8:9147–9153. 2015.PubMed/NCBI
|
|
37
|
Li L, Sarver AL, Khatri R, Hajeri PB,
Kamenev I, French AJ, Thibodeau SN, Steer CJ and Subramanian S:
Sequential expression of miR-182 and miR-503 cooperatively targets
FBXW7, contributing to the malignant transformation of colon
adenoma to adenocarcinoma. J Pathol. 234:488–501. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhou C, Shen L, Mao L, Wang B, Li Y and Yu
H: miR-92a is upregulated in cervical cancer and promotes cell
proliferation and invasion by targeting FBXW7. Biochem Biophys Res
Commun. 458:63–69. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang H, Yang Z, Liu C, Huang S, Wang H,
Chen Y and Chen G: RBP-J-interacting and tubulin-associated protein
induces apoptosis and cell cycle arrest in human hepatocellular
carcinoma by activating the p53-FBW7 pathway. Biochem Biophys Res
Commun. 454:71–77. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Huang H, Ma L, Li J, Yu Y, Zhang D, Wei J,
Jin H, Xu D, Gao J and Huang C: NF-κB1 inhibits c-Myc protein
degradation through suppression of FBW7 expression. Oncotarget.
5:493–505. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Min SH, Lau AW, Lee TH, Inuzuka H, Wei S,
Huang P, Shaik S, Lee DY, Finn G, Balastik M, et al: Negative
regulation of the stability and tumor suppressor function of Fbw7
by the Pin1 prolyl isomerase. Mol Cell. 46:771–783. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang Z, Liu Y, Zhang P, Zhang W, Wang W,
Curr K, Wei G and Mao JH: FAM83D promotes cell proliferation and
motility by downregulating tumor suppressor gene FBXW7. Oncotarget.
4:2476–2486. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jiang X, Xing H, Kim TM, Jung Y, Huang W,
Yang HW, Song S, Park PJ, Carroll RS and Johnson MD: Numb regulates
glioma stem cell fate and growth by altering epidermal growth
factor receptor and Skp1-Cullin-F-box ubiquitin ligase activity.
Stem Cells. 30:1313–1326. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Peirs S, Van der Meulen J, Van de Walle I,
Taghon T, Speleman F, Poppe B and Van Vlierberghe P: Epigenetics in
T-cell acute lymphoblastic leukemia. Immunol Rev. 263:50–67. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Pui CH and Evans WE: Treatment of acute
lymphoblastic leukemia. N Engl J Med. 354:166–178. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Vadillo E, Dorantes-Acosta E, Pelayo R and
Schnoor M: T cell acute lymphoblastic leukemia (T-ALL): New
insights into the cellular origins and infiltration mechanisms
common and unique among hematologic malignancies. Blood Rev.
32:36–51. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Allen A, Sireci A, Colovai A, Pinkney K,
Sulis M, Bhagat G and Alobeid B: Early T-cell precursor
leukemia/lymphoma in adults and children. Leuk Res. 37:1027–1034.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Pui CH, Robison LL and Look AT: Acute
lymphoblastic leukaemia. Lancet. 371:1030–1043. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Matsuoka S, Oike Y, Onoyama I, Iwama A,
Arai F, Takubo K, Mashimo Y, Oguro H, Nitta E, Ito K, et al: Fbxw7
acts as a critical fail-safe against premature loss of
hematopoietic stem cells and development of T-ALL. Genes Dev.
22:986–991. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Onoyama I, Tsunematsu R, Matsumoto A,
Kimura T, de Alborán IM, Nakayama K and Nakayama KI: Conditional
inactivation of Fbxw7 impairs cell-cycle exit during T cell
differentiation and results in lymphomatogenesis. J Exp Med.
204:2875–2888. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kwon YW, Kim IJ, Wu D, Lu J, Stock WA Jr,
Liu Y, Huang Y, Kang HC, DelRosario R, Jen KY, et al: Pten
regulates Aurora-A and cooperates with Fbxw7 in modulating
radiation-induced tumor development. Mol Cancer Res. 10:834–844.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
King B, Trimarchi T, Reavie L, Xu L,
Mullenders J, Ntziachristos P, Aranda-Orgilles B, Perez-Garcia A,
Shi J, Vakoc C, et al: The ubiquitin ligase FBXW7 modulates
leukemia-initiating cell activity by regulating MYC stability.
Cell. 153:1552–1566. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
King B, Trimarchi T, Reavie L, Xu L,
Mullenders J, Ntziachristos P, Aranda-Orgilles B, Perez-Garcia A,
Shi J and Vakoc C: Regulation of leukemia-initiating cell activity
by the ubiquitin ligase FBXW7. Cell. 153:1552–1566. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Thompson BJ, Jankovic V, Gao J, Buonamici
S, Vest A, Lee JM, Zavadil J, Nimer SD and Aifantis I: Control of
hematopoietic stem cell quiescence by the E3 ubiquitin ligase Fbw7.
J Exp Med. 205:1395–1408. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Tosello V and Ferrando AA: The NOTCH
signaling pathway: Role in the pathogenesis of T-cell acute
lymphoblastic leukemia and implication for therapy. Ther Adv
Hematol. 4:199–210. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Arruga F, Gizdic B, Bologna C, et al:
Mutations in NOTCH1 PEST domain orchestrate CCL19-driven homing of
chronic lymphocytic leukemia cells by modulating the tumor
suppressor gene DUSP22. 31:18822017.PubMed/NCBI
|
|
57
|
Chiang MY, Radojcic V and Maillard I:
Oncogenic Notch signaling in T-cell and B-cell lymphoproliferative
disorders. Curr Opin Hematol. 23:362–370. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Grabher C, von Boehmer H and Look AT:
Notch 1 activation in the molecular pathogenesis of T-cell acute
lymphoblastic leukaemia. Nat Rev Cancer. 6:347–359. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Suresh S and Irvine AE: The NOTCH
signaling pathway in normal and malignant blood cell production. J
Cell Commun Signal. 9:5–13. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Malecki MJ, Sanchez-Irizarry C, Mitchell
JL, Histen G, Xu ML, Aster JC and Blacklow SC: Leukemia-associated
mutations within the NOTCH1 heterodimerization domain fall into at
least two distinct mechanistic classes. Mol Cell Biol.
26:4642–4651. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
O'Neil J, Grim J, Strack P, Rao S,
Tibbitts D, Winter C, Hardwick J, Welcker M, Meijerink JP, Pieters
R, et al: FBW7 mutations in leukemic cells mediate NOTCH pathway
activation and resistance to γ-secretase inhibitors. J Exp Med.
204:1813–1824. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Kumar V, Palermo R, Talora C, Campese AF,
Checquolo S, Bellavia D, Tottone L, Testa G, Miele E, Indraccolo S,
et al: Notch and NF-kB signaling pathways regulate miR-223/FBXW7
axis in T-cell acute lymphoblastic leukemia. Leukemia.
28:2324–2335. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Malyukova A, Brown S, Papa R, O'Brien R,
Giles J, Trahair TN, Dalla Pozza L, Sutton R, Liu T, Haber M, et
al: FBXW7 regulates glucocorticoid response in T-cell acute
lymphoblastic leukaemia by targeting the glucocorticoid receptor
for degradation. Leukemia. 27:1053–1062. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Yang-Yen HF: Mcl-1: A highly regulated
cell death and survival controller. J Biomed Sci. 13:201–204. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Inuzuka H, Shaik S, Onoyama I, Gao D,
Tseng A, Maser RS, Zhai B, Wan L, Gutierrez A, Lau AW, et al:
SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for
ubiquitylation and destruction. Nature. 471:104–109. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Wertz IE, Kusam S, Lam C, Okamoto T,
Sandoval W, Anderson DJ, Helgason E, Ernst JA, Eby M, Liu J, et al:
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1
and FBW7. Nature. 471:110–114. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Schwickart M, Huang X, Lill JR, Liu J,
Ferrando R, French DM, Maecker H, O'Rourke K, Bazan F,
Eastham-Anderson J, et al: Deubiquitinase USP9X stabilizes MCL1 and
promotes tumour cell survival. Nature. 463:103–107. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Katsuya H, Ishitsuka K, Utsunomiya A,
Hanada S, Eto T, Moriuchi Y, Saburi Y, Miyahara M, Sueoka E, Uike
N, et al ATL-Prognostic Index Project, : Treatment and survival
among 1594 patients with ATL. Blood. 126:2570–2577. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Yeh C-H, Bellon M, Pancewicz-Wojtkiewicz J
and Nicot C: Oncogenic mutations in the FBXW7 gene of adult T-cell
leukemia patients. Proc Natl Acad Sci USA. 113:6731–6736. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Mihashi Y, Mizoguchi M, Takamatsu Y,
Ishitsuka K, Iwasaki H, Koga M, Urabe K, Momosaki S, Sakata T,
Kiyomi F, et al: C-MYC and its main ubiquitin ligase, FBXW7,
influence cell proliferation and prognosis in adult T-cell
leukemia/lymphoma. Am J Surg Pathol. 41:1139–1149. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Chiorazzi N, Rai KR and Ferrarini M:
Chronic lymphocytic leukemia. N Engl J Med. 352:804–815. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Kipps TJ, Stevenson FK, Wu CJ, Croce CM,
Packham G, Wierda WG, O'Brien S, Gribben J and Rai K: Chronic
lymphocytic leukaemia. Nat Rev Dis Primers. 3:160962017. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Bosch F and Dalla-Favera R: Chronic
lymphocytic leukaemia: From genetics to treatment. Nat Rev Clin
Oncol. 16:684–701. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Landau DA, Tausch E, Taylor-Weiner AN,
Stewart C, Reiter JG, Bahlo J, Kluth S, Bozic I, Lawrence M,
Böttcher S, et al: Mutations driving CLL and their evolution in
progression and relapse. Nature. 526:525–530. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Jeromin S, Weissmann S, Haferlach C,
Dicker F, Bayer K, Grossmann V, Alpermann T, Roller A, Kohlmann A,
Haferlach T, et al: SF3B1 mutations correlated to cytogenetics and
mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated
CLL patients. Leukemia. 28:108–117. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Quijada-Álamo M, Hernández-Sánchez M,
Robledo C, Hernández-Sánchez JM, Benito R, Montaño A,
Rodríguez-Vicente AE, Quwaider D, Martín AÁ, García-Álvarez M, et
al: Next-generation sequencing and FISH studies reveal the
appearance of gene mutations and chromosomal abnormalities in
hematopoietic progenitors in chronic lymphocytic leukemia. J
Hematol Oncol. 10:832017. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Close V, Close W, Kugler SJ, Reichenzeller
M, Yosifov DY, Bloehdorn J, Pan L, Tausch E, Westhoff MA, Döhner H,
et al: FBXW7 mutations reduce binding of NOTCH1, leading to cleaved
NOTCH1 accumulation and target gene activation in CLL. Blood.
133:830–839. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Palumbo A and Anderson K: Multiple
myeloma. N Engl J Med. 364:1046–1060. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Sonneveld P, Avet-Loiseau H, Lonial S,
Usmani S, Siegel D, Anderson KC, Chng WJ, Moreau P, Attal M, Kyle
RA, et al: Treatment of multiple myeloma with high-risk
cytogenetics: A consensus of the International Myeloma Working
Group. Blood. 127:2955–2962. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Annunziata CM, Davis RE, Demchenko Y,
Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W,
et al: Frequent engagement of the classical and alternative
NF-kappaB pathways by diverse genetic abnormalities in multiple
myeloma. Cancer Cell. 12:115–130. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Jourdan M, Moreaux J, De Vos J, Hose D,
Mahtouk K, Abouladze M, Robert N, Baudard M, Rème T, Romanelli A,
et al: Targeting NF-kappaB pathway with an IKK2 inhibitor induces
inhibition of multiple myeloma Cell Proliferation. Br J Haematol.
138:160–168. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Sun SC: The non-canonical NF-κB pathway in
immunity and inflammation. Nat Rev Immunol. 17:545–558. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Senftleben U, Cao Y, Xiao G, Greten FR,
Krähn G, Bonizzi G, Chen Y, Hu Y, Fong A, Sun SC, et al: Activation
by IKKalpha of a second, evolutionary conserved, NF-kappa B
signaling pathway. Science. 293:1495–1499. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Busino L, Millman SE and Pagano M:
SCF-mediated degradation of p100 (NF-κB2): Mechanisms and relevance
in multiple myeloma. Sci Signal. 5:pt142012. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Frassanito MA, Rao L, Moschetta M, Ria R,
Di Marzo L, De Luisi A, Racanelli V, Catacchio I, Berardi S, Basile
A, et al: Bone marrow fibroblasts parallel multiple myeloma
progression in patients and mice: In vitro and in vivo studies.
Leukemia. 28:904–916. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Frassanito MA, De Veirman K, Desantis V,
Di Marzo L, Vergara D, Ruggieri S, Annese T, Nico B, Menu E,
Catacchio I, et al: Halting pro-survival autophagy by TGFβ
inhibition in bone marrow fibroblasts overcomes bortezomib
resistance in multiple myeloma patients. Leukemia. 30:640–648.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Frassanito MA, Desantis V, Di Marzo L,
Craparotta I, Beltrame L, Marchini S, Annese T, Visino F, Arciuli
M, Saltarella I, et al: Bone marrow fibroblasts overexpress miR-27b
and miR-214 in step with multiple myeloma progression, dependent on
tumour cell-derived exosomes. J Pathol. 247:241–253. 2019.
View Article : Google Scholar : PubMed/NCBI
|
